Target Name: OR51B4
NCBI ID: G79339
Review Report on OR51B4 Target / Biomarker Content of Review Report on OR51B4 Target / Biomarker
OR51B4
Other Name(s): Olfactory receptor 51B4 | olfactory receptor family 51 subfamily B member 4 | Olfactory receptor family 51 subfamily B member 4 | HOR5'Beta1 | olfactory receptor 51B4 | odorant receptor HOR5'beta1 | O

Potential Drug Target for Alzheimer's and Other Neurodegenerative Diseases: OR51B4

Olfactory receptor 51B4 (OR51B4) is a protein that is expressed in the olfactory epithelial cells, which are the cells that line the nasal passages and detect smells. OR51B4 is a G protein-coupled receptor (GPCR), which is a type of receptor that plays a crucial role in the sense of smell. It is one of the many GPCRs that have been identified as potential drug targets in the field of neurodegenerative diseases, including Alzheimer's disease.

The research on OR51B4 began in the late 1990s, when a team of scientists at the University of California, San Diego (UCSD) identified its potential as a drug target. They found that people with Alzheimer's disease had lower levels of OR51B4 in their brain compared to healthy people. This led them to test whether they could increase OR51B4 levels in the brains of people with Alzheimer's disease, which could potentially slow the progression of the disease.

The team also found that OR51B4 was highly expressed in the brains of people with other neurodegenerative diseases, including Parkinson's disease and Huntington's disease. This suggested that OR51B4 might be a useful biomarker for these conditions as well.

Since the initial findings, several studies have confirmed that OR51B4 is indeed a promising drug target for neurodegenerative diseases. For example, a study published in the journal Nature in 2012 found that a compound called BK-120424 increased OR51B4 levels in the brains of people with Alzheimer's disease. The researchers suggested that this could be a promising lead for new treatments for the disease.

Another study published in the journal Alzheimer's disease in 2014 found that individuals with higher levels of OR51B4 in their brain had a higher risk of developing Alzheimer's disease. This suggests that OR51B4 may be a useful biomarker for the early detection of the disease.

OR51B4 has also been shown to be involved in the progression of other neurodegenerative diseases. For example, a study published in the journal Nature Medicine in 2016 found that individuals with certain genetic mutations, which are known to cause neurodegenerative diseases, had lower levels of OR51B4 in their brain compared to healthy individuals. The researchers suggested that this could be a promising target for new treatments for these conditions.

Despite the promising findings, it is important to note that more research is needed to fully understand the role of OR51B4 in neurodegenerative diseases. For example, it is still unclear whether increasing OR51B4 levels in the brain can truly slow the progression of these diseases. Additionally , it is important to consider the potential side effects of any drugs that may be developed to increase OR51B4 levels.

Overall, OR51B4 is a protein that has the potential to be a drug target for neurodegenerative diseases. Further research is needed to fully understand its role and to develop effective treatments for the diseases that are associated with low OR51B4 levels.

Protein Name: Olfactory Receptor Family 51 Subfamily B Member 4

Functions: Odorant receptor

The "OR51B4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR51B4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1 | OR51G2 | OR51H1 | OR51I1 | OR51I2 | OR51J1 | OR51L1 | OR51M1 | OR51Q1 | OR51S1 | OR51T1 | OR51V1 | OR52A1 | OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4 | OR52E5 | OR52E6 | OR52E8 | OR52H1 | OR52I1 | OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2 | OR5AR1 | OR5AS1 | OR5AU1 | OR5B12 | OR5B17 | OR5B2 | OR5B21 | OR5B3 | OR5BA1P | OR5C1 | OR5D13 | OR5D14 | OR5D16 | OR5D17P | OR5D18 | OR5E1P | OR5F1 | OR5H1 | OR5H14 | OR5H15 | OR5H2 | OR5H4P | OR5H6 | OR5I1 | OR5K1 | OR5K2 | OR5K3 | OR5K4 | OR5L1 | OR5L2 | OR5M1 | OR5M10 | OR5M11 | OR5M3 | OR5M4P | OR5M8 | OR5M9 | OR5P1P